Open AccessLong‐term outcomes of late course accelerated hyper‐fractionated radiotherapy for localized esophageal carcinoma in Mainland China: a meta‐analysis
Author(s) -
Zhang Y. W.,
Chen L.,
Bai Y.,
Zheng X.
Publication year - 2011
Publication title -
diseases of the esophagus
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.115
H-Index - 63
eISSN - 1442-2050
pISSN - 1120-8694
DOI - 10.1111/j.1442-2050.2010.01173.x
Subject(s) - medicine , meta analysis , radiation therapy , confidence interval , odds ratio , randomized controlled trial , carcinoma , oncology , surgery
SUMMARY Published data on the long‐term survival results of patients with localized esophageal carcinoma receiving late course accelerated hyper‐fractionated radiotherapy (LCAF RT) versus conventional fractionated radiotherapy (CF RT) are inconclusive. In order to derive a more precise estimation of the both treatment‐regimes, a meta‐analysis based on systematic review of published articles was performed. A meta‐analysis was performed using trials identified through Pubmed and Chinese national knowledge infrastructure. Results in 5‐year survival and 5‐year local control were collected from randomized trials comparing LCAF RT with CF RT. Review Manager (The Cochrane Collaboration, Oxford, England) and Stata software (Stata Corporation, College Station, TX, USA) were used for data management. A total of 11 trials were involved in this analysis with 572 cases and 567 controls. Our results showed that LCAF RT, compared with CF RT, significantly improved the 5‐year survival (odds ratio [OR]= 2.93, 95% confidence interval [CI]: 2.15–4.00, P < 0.00001) and 5‐year local control (OR = 3.96, 95% CI: 2.91–5.38, P < 0.00001). LCAF RT was more therapeutically beneficial than CF RT in the localized esophageal carcinoma.